Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $116000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 26.58% year-over-year to $116000.0 in Q1 2026; TTM through Mar 2026 was $570000.0, a 11.35% decrease from a year earlier, with the FY2025 full-year figure at $612000.0, down 7.69% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $116000.0, down from $139000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for NAGE reached as high as $235000.0 in Q3 2022 and fell as low as $116000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $184117.6 across 5 years, with a median of $177000.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) gained 13.43% in 2023 and fell 29.61% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $221000.0 in 2022, then dropped by 19.91% to $177000.0 in 2023, then dropped by 14.69% to $151000.0 in 2024, then slipped by 7.95% to $139000.0 in 2025, then retreated by 16.55% to $116000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $116000.0 in Q1 2026, $139000.0 in Q4 2025, and $157000.0 in Q3 2025.